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Abstract
Background: Adequate foetal growth is primarily determined by nutrient availability, which is dependent on placental
nutrient transport and foetal metabolism. We have used
1H nuclear magnetic resonance (NMR) spectroscopy to probe the
metabolic adaptations associated with premature birth.
Methodology: The metabolic profile in
1H NMR spectra of plasma taken immediately after birth from umbilical vein,
umbilical artery and maternal blood were recorded for mothers delivering very-low-birth-weight (VLBW) or normo-ponderal
full-term (FT) neonates.
Principal Findings: Clear distinctions between maternal and cord plasma of all samples were observed by principal
component analysis (PCA). Levels of amino acids, glucose, and albumin-lysyl in cord plasma exceeded those in maternal
plasma, whereas lipoproteins (notably low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) and lipid levels
were lower in cord plasma from both VLBW and FT neonates. The metabolic signature of mothers delivering VLBW infants
included decreased levels of acetate and increased levels of lipids, pyruvate, glutamine, valine and threonine. Decreased
levels of lipoproteins glucose, pyruvate and albumin-lysyl and increased levels of glutamine were characteristic of cord
blood (both arterial and venous) from VLBW infants, along with a decrease in levels of several amino acids in arterial cord
blood.
Conclusion: These results show that, because of its characteristics and simple non-invasive mode of collection, cord plasma
is particularly suited for metabolomic analysis even in VLBW infants and provides new insights into the materno-foetal
nutrient exchange in preterm infants.
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Introduction
The human foetus triples its weight during the last trimester of
pregnancy, and is entirely dependent on ‘imported’ nutrients to
cover its protein and energy needs. As protein accretion is a
prerequisite for growth, the supply of amino acids from the
maternal circulation is crucial to support foetal growth. The
transfer of amino acids across the placenta from maternal to foetal
circulations is complex [1] as three barriers are involved: nutrients
are first taken up from the maternal circulation across the
microvillous membrane, diffuse through the cellular cytoplasm,
and finally are transported across the placental basal membrane
into the umbilical circulation [2]. The first step of the transfer of
amino acids and glucose through the placenta has been well
studied but the transfer towards the foetus is less well described [2–
4]. Understanding this process and its regulation will help develop
interventional nutritional strategies, particularly in situations such
as intrauterine growth restriction (IUGR) or preterm delivery
when materno-foetal transfer is impaired (see [1] and refs therein)
or foetal substrate synthesis is inadequate [5,6].
During normal pregnancy, the concentration of most amino
acids is higher in foetal than in maternal plasma. Several studies
[2,6–9] have shown that overall amino acid concentration is
decreased in foetuses with IUGR, particularly for branched-chain
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plasma concentrations. Accordingly, the rate of materno-foetal
amino acid transfer, which can be assessed with techniques
exploiting the infusion of stable-isotope-labelled amino acids, is
reduced in IUGR infants, compared with control babies [10] and
the drop in the materno-foetal isotope enrichment ratio depends
on the severity of IUGR [11]. Amino acid transfer was also found
to be affected by prematurity [12], maternal diabetes [13] or
hypoxia [14].
In addition, deficiencies in maternal plasma can obviously affect
foetal nutrient supply, and it is essential to establish whether
insufficiency is related to altered materno-foetal supply or to foetal
metabolism. As an example, we have recently shown that very low
birth weight (VLBW) preterm neonates possess a fully active
capacity to synthesize glutathione (GSH), a key antioxidant, and
that the observed depletion in umbilical blood may arise from
inadequate cysteine availability from the maternal venous blood
supply to the placenta [15].
Most studies of materno-foetal nutrient gradients have focused
on specific nutrients, and do not provide a full-picture of nutrient
supply to the foetus. Apart from amino acids [1,10–14], the
materno-foetal exchange of other essential nutrients has been
poorly explored. Furthermore, transfer across the placenta of other
substrates, such as those involved in energy metabolism, has not
been adequately investigated.
To get further insight into the materno-foetal nutrient transfer
and assess metabolic profiles of the VLBW neonates and their
mothers, a metabolomic approach based on nuclear magnetic
resonance (NMR) spectroscopy has been adopted, as we believe
this offers the best prospect to highlight potential metabolic
deregulation in VLBW infants. The advantage of using high
resolution
1H NMR metabolomic profiling is that it is possible to
assess the main plasma proton-containing metabolites even at sub-
mM concentrations in a body fluid, with an excellent precision and
reproducibility [16].
The most commonly used biological fluids sampled for
metabolomics studies are urine, blood plasma or serum. However,
the use of non-invasive methods is an essential requirement in
neonatal medicine, especially in studying VLBW infants. Although
the metabolomic analysis of urine has been used to assess the
overall metabolic status of term and preterm neonates [17,18] and
is appropriate to explore postnatal metabolic maturation, it does
not provide any insight into prenatal metabolite supply and
materno-foetal substrate transfer at birth. One previous study
using
1H NMR spectroscopy to examine plasma collected from
umbilical and maternal veins of mothers delivering healthy
normo-ponderal full-term (FT) neonates has been reported [19].
While this study surveyed the presence of lactate, alanine, valine,
and lipoproteins in maternal and cord venous blood, neither
umbilical arterial blood plasma nor the effect of VLBL were
analyzed.
The working hypothesis adopted is that there will be general
changes that can be associated with preterm natural delivery. In
order to seek general metabolic differences between term and
preterm deliveries, we have included in our study VLBW group
subjects with a known state of disease (diabetes), with pregnancy-
induced hypertension and with no evident identified cause of
premature delivery. We also include natural delivery and delivery
by caesarean section. Hence, we aim to obtain insight into the
materno-foetal metabolite exchange without any particular bias.
For this group, and a control group of FT normal delivery
subjects, we report a metabolomic analysis on plasma from three
sources: the umbilical vein, which provides information about
blood directed from the placenta to the foetus; one of the two
umbilical arteries, representing blood of the foetus redistributed to
the placenta; the maternal venous blood collected at delivery, in
order to relate information obtained from umbilical blood to the
status of the mothers.
Materials and Methods
Patients
The study was carried out on 8 VLBW infant-mother pairs and
8 control FT infant-mother pairs. The size of the population, while
small, proved adequate to identify a number of biomarkers (see
below). In view of the difficulty of recruiting members of the
VLBW test set, due to both the unpredictability of premature birth
and to the ethical requirement of not perturbing the mother at this
stressful moment, we did not extend this initial study further.
The study group consisted of:
(a) a test set of 8 inborn very-low-birth-weight (VLBW)
neonates. Inclusion criteria were a gestational age (GA)
,32 weeks and/or a birth weight ,1500 g. The gestational
age was between 6 and 14 weeks premature. Exclusion
criteria were: perinatal asphyxia or major foetal pathology
(abnormal karyotype, malformation, foetal pathology re-
vealed during pregnancy);
(b) a control set of 8 inborn normo-ponderal full term (FT)
neonates. Inclusion criteria for the control group were: a GA
.37 weeks, and an uneventful pregnancy and delivery.
Exclusion criteria for the control group were: perinatal
asphyxia, major foetal pathology, bacterial or viral infection,
or maternal arterial blood pressure .90 mm Hg during
pregnancy;
(c) the 16 mothers of the VLBW and FT infants.
Table 1 gives the clinical parameters for the 16 neonates and
their mothers.
Written, informed consent was obtained from each mother a
few hours before delivery, according to a protocol approved by the
local medical ethical committee (Comite ´ de Protection des
Personnes dans la recherche biome ´dicale (CPP) des Pays de la
Loire).
The study was registered (ClinicalTrials.gov Identifier:
NCT00607061), and performed in the Department of Obstetrics
of the Hospital Mere-et-Enfant at the University of Nantes,
Nantes. We confirm that our ethics committee specifically
approved this study.
Sample collection and preparation
Samples of arterial and venous umbilical cord blood were
obtained immediately after birth. The sampling only used
umbilical cord blood and did not involve any blood loss for the
neonates. Maternal venous blood was collected at delivery for each
mother-neonate pair included in order to obtain materno-infant
pairs for comparison between the preterm delivery (VLBW) and
the control (FT) groups. Samples were collected in chilled 5-mL
EDTA-coated tubes. The plasma was separated immediately by
centrifugation (5000 g, 10 min, 4uC) and stored at 220uC until
required for NMR analysis.
1H NMR spectroscopy measurement of maternal and
umbilical arterial and venous plasma
Samples were prepared from a plasma volume of 150 mL and
450 mL of a mixture of H2O/D2O (70/30% volume) in a 5 mm
NMR tube.
1H NMR of Maternal and Cord Plasma
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recorded at 303 K on a Bruker Avance DRX-500 spectrometer
(Bruker, Karlsruhe, Germany), operating at 500.13 MHz for
proton and equipped with a cryogenic probe. Standard methods
for the acquisition of plasma NMR spectra were used [20]. 1D
1H
NMR spectra were acquired using the NOESYPR1D (1D Nuclear
Overhauser effect spectroscopy with water pre-saturation) pulse
sequence (RD-90u-t1-90u-tm-90u-acquire) with a relaxation delay
(RD) of 2 s, a mixing time (tm) of 150 ms and a fixed t1 delay of
20 ms. Water suppression was achieved by pre-saturation during
the relaxation delay and mixing time. Each spectrum consisted of
128 free induction decays (FIDs) collected into 32K complex data
points with a spectral width of 8012.8 Hz and an acquisition time
of 2 s.
1D relaxation-edited
1H NMR spectra were acquired using the
water suppressed Carr-Purcell-Meiboom-Gill (CPMG) spin echo
pulse sequence (RD-90u-{t-180u- t}n-acquire) with a relaxation
delay of 2 s and a total spin-spin relaxation time (2 n t) of 200 ms
in order to attenuate broad signals from proteins and lipoproteins.
256 FIDs were collected into 32K complex data points.
Prior to Fourier transformation, the FIDs were zero-filled to
64K points and multiplied by an exponential line-broadening
function of 0.3 Hz. The 1D spectra were manually phased,
baseline corrected, and the chemical shifts referenced internally to
the a-glucose signal at d 5.234 ppm, using Topspin
TM software
(Bruker, Karlsruhe, Germany).
Data processing and chemometric analyses
Each
1H NMR spectrum of NOESYPR1D and CPMG
sequences over the range (d 0.7–8.5 ppm) was reduced to 70
and 92 segments, respectively. Using AMIX
TM software (version
3.8.4, Bruker, Karlsruhe, Germany), segments were defined
manually so as each to contain a single metabolite. Segments
thus defined covered 99.5% of the spectrum. Signal intensity in
each segment was integrated using AMIX software. Data was
normalized in AMIX by dividing each integrated segment by the
total area of the spectrum to reduce any significant concentration
difference. Output data in ASCII data format was imported to
Excel 2003 (Microsoft Corporation, Redmond WA, USA), mean
centred and then exported to SIMCA-P+ (version 12.0, Umetrics,
Umea ˚, Sweden) for statistical analyses.
Statistical analysis of
1H NMR spectroscopic data
For each set of spectra (NOESYPR1D and CPMG), a data
matrix was built, where each row corresponds to a sample, each
column to a chemical shift and each value in the data table to the
sum of the intensities of an NMR segment. The water region (d
4.5–5.0 ppm) and the segments containing EDTA-related signals
(d 2.53–2.58, 3.1–3.3, 3.6–3.7 ppm) were excluded. Chemometric
analysis was performed using SIMCA-P+. Initial data analyses
were conducted using the unsupervised method of Principal
Component Analysis (PCA). The NMR variables responsible for
the differences between sample scores in the score plot can be
detected in the corresponding loading plot [21]. In addition, a
supervised method, Partial Least Squares Discriminant Analysis
(PLS-DA), was applied to maximize the discrimination between
sample groups focusing on differences according to preterm
subject metabolic variations [22].
The quality of the PLS-DA models obtained was evaluated by
three parameters: R
2(X), corresponding to the proportion of the
total variance of the dependant variables that is explained by the
model, R
2(Y), defining the proportion of the total variance of the
response variable (i.e. the class of the samples) explained by the
model, and the predictive ability parameter Q
2(Y), which is similar
to R
2(Y) except that it is computed by cross-validation. In addition,
a permutation test (n=20) was carried out to validate and to test
Table 1. Selected clinical characteristics of enrolled infants and their mothers.
Group
Preterm VLBW subjects FT subjects
(n=8) (n=8) p
{
Sex
Male, n 3 (37%) 3 (37%)
Female, n 5 (63%) 5 (63%)
Birth weight, g 1180 [940–1351] 3320 [3098–3429] ,0.001
Gestational age, wk 28.9 [27.4–30.0] 40.2 [39.6–41.0] ,0.001
Birth weight, z score
pH in umbilical cord blood 7.3 [7.2–7.4] 7.3 [7.2–7.4]
Mode of delivery
Vaginal, n 3 (37%) 8 (100%)
Caesarean section, n 5 (63%) 0 (0%)
Preeclampsia, n 3 (37%) 0 (0%)
Apgar score at 5 min 10 [8–10] 10 [10–10] 0.06
Infant haemoglobin g/dl 15.5 [14.3–17.5] 17.5 [14.7–18.1] 0.88
Maternal age, y 31.7 [27.7–36.1] 28.8 [27.1–32.1] 0.34
Maternal haemoglobin g/dl 11.6 [10.7–12.1] 12.7 [12.2–13.0] 0.02
Maternal hypertension 5 (63%) 0 (0%)
Data are reported as n (%) or median [interquartile 25–75].
{Inter-group comparison by Mann-Whitney U test.
doi:10.1371/journal.pone.0029947.t001
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29947Figure 1. 500 MHz
1H NMR spectra of arterial umbilical cord plasma from a VLBW delivery. (A) standard NOESYPR1D spectrum; (B) 1D
relaxation–edited (CPMG) spectrum. Assignment: 1, HDL; 2, LDL; 3, VLDL; 4, valine; 5, leucine; 6, isoleucine; 7, lactate; 8, alanine; 9; lipid; 10, N-acetyl
glycoprotein; 11, unsaturated lipid; 12, b-hydroxybutyrate; 13, lipid; 14, acetate; 15, glutamine; 16, acetone; 17, pyruvate; 18, succinate; 19, albumin-
lysyl; 20, creatinine; 21, glucose; 22, threonine; 23, tyrosine; 24, methylhistidine; 25, phenylalanine; 26, formate.
doi:10.1371/journal.pone.0029947.g001
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coefficient between the original Y and the permuted Y is plotted
against the cumulative R
2 and Q
2 and a regression line is
calculated with the R
2- and Q
2-intercept limits. The model was
successfully validated when R
2(Y) and Q
2(Y).0.6 and observed
intercept values of R
2(Y) and Q
2(Y),R
2(Y) and Q
2(Y), respec-
tively. The score values from PLS-DA were subjected to ANOVA
to test the PLS-DA model and the validation was considered
successful with p,0.05.
The variables which discriminate most significantly the metabolic
signatures were pinpointed by their loadings on PLS-DA. The
significance of the differences was further assessed by comparing the
area normalized intensity of metabolite signals between the preterm
and full-term plasma samples with the non parametric Mann
Whitney U test. The critical p value was set at 0.05.
Results
Feasibility of
1H NMR spectroscopy for the analysis of
arterial and venous umbilical cord plasma and maternal
plasma
Ethical constraints limit both the number of samples and the
volume of blood that can be used for studies in new-born infants.
However, samples of umbilical venous and umbilical arterial blood
taken at parturition represent the placental supply to the foetus,
and foetal arterial blood, respectively. Although it is difficult to
obtain more than 150 mL of placental arterial blood plasma, this
volume proved sufficient to obtain
1H NMR NOESYPR1D and
CPMG spectra of arterial umbilical cord plasma in VLBW infants,
as illustrated in Figure 1A and 1B. Similarly, spectra were also
obtained from 150 mL samples of arterial umbilical cord plasma
collected from FT infants at birth and from maternal venous
plasma and venous umbilical cord plasma, both for FT and
VLBW deliveries (spectra not shown). Such small volumes of
untreated plasma samples (150 mL) proved sufficient for the
detection and estimation of a wide range of metabolites in FT and
VLBW infant plasmas.
Metabolite profiles of arterial and venous umbilical cord
plasma and maternal plasma obtained by
1H NMR
spectroscopy
Based on the literature [23,24], twenty six metabolites were
identified from the two spectral types acquired, NOESYPR1D
(Figure 1A) and CPMG (Figure 1B). As typically observed, the
NOESYPR1D spectrum is dominated by the broad resonances of
lipoproteins and other plasma proteins, which mask the signals from
low-molecular-weight metabolites. In contrast, by employing the
CPMG pulse sequence to attenuate or even eliminate resonances
from macromolecules (or bound small molecules) with shorter
relaxation times [23,25], the spectrum acquired (Figure 1B), gives
a clear representation of the low-molecular-weight metabolites
present, especially in the low-frequency (d 0–3 ppm) and high-
frequency (d 6–10 ppm) regions of the spectrum. The metabolites
identified in Figure 1 cover a typical range of low molecular weight
compounds found in plasma, including amino acids, glycolysis
metabolites, ketone bodies, and higher molecular mass metabolites
including lipoproteins, unsaturated lipids, glycoproteins, and
albumin-lysyl, as indicated by the signals corresponding to the N-
acetyl groups and lysyl groups, respectively.
Venous umbilical cord plasma (450 mL) and maternal plasma
taken at FT delivery have previously been examined by
1H NMR
spectrometry and some of these metabolites identified [19]. In this
earlier study, the Hahn spin echo sequence was used, which did
not allow signals in the aromatic region to be detected.
Nevertheless, metabolites such as b-hydroxybutyrate, valine,
alanine, glutamine and the N-acetyl groups of glycoproteins from
plasma proteins were identified [19]. Arterial umbilical cord blood
plasma, which represents blood supply from the foetus, was not
examined by these authors. In fact, it is relatively difficult to obtain
a sufficiently large sample of arterial cord blood for
1H NMR
Figure 2. Multivariate analyses resulting from the 48 standard 1D spectra of maternal and both venous and arterial cord plasma
from FT and VLBL deliveries. (A): PCA scores plot. (B): PCA loadings plot. The maternal plasma and both venous and arterial cord plasma are
clearly distinguished on the first component which accounts for 54% of the total variance. The second component, which account for 14% of the
total variance is related to inter-individual differences.
doi:10.1371/journal.pone.0029947.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29947Figure 3. 500 MHz 1H NMR CPMG spectra of blood plasma samples from VLBW deliveries. (A) Arterial cord blood, (B) Venous cord blood
(C) Maternal blood. The same spectral profile was obtained for arterial and venous blood plasma, whereas the spectrum of maternal blood plasma
was different. The differences are marked by +.
doi:10.1371/journal.pone.0029947.g003
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of only 150 mL and showed that it is possible therein to identify
simultaneously 26 metabolites (Figure 1A and 1B). Thus, three
plasmas obtained from three different sites –arterial and venous
umbilical cord blood and maternal venous blood –can be studied
under comparable conditions, indicating that
1H NMR spectrom-
etry may be an exploitable tool in neonatal research.
Discussion
Clear-cut differences are observed between umbilical
arterial, umbilical venous and maternal plasma by PCA
Plasma samples collected at the three different sites for VLBW
preterm and FT deliveries were assessed using PCA analysis to
determine the most important sources of variability between the
samples collected from the three different blood origins. The scores
scatter plot resulting from applying PCA to the NOESYPR1D
spectra (water and EDTA signals excluded) is shown in Figure 2A.
Regardless of gestational age, a clear separation between maternal
and venous/arterial umbilical cord plasma was observed along
principal component 1 (PC1 54%). Figure 2B represents the
loading plot corresponding to the first two PCs of the PCA model.
The metabolic variations based on the PCs loading orientations
showed higher levels of amino acids, glucose, HDL, albumin-lysyl
and lower levels of lipids, LDL, VLVL, N-acetyl groups of
glycoproteins, acetoacetate, and b-hydroxybutyrate in both arterial
and venous umbilical cord plasma compared with maternal plasma.
Figure 3 illustrates
1H NMR metabolomic spectra of umbilical
arterial (Figure 3A), umbilical venous (Figure 3B) and maternal
(Figure 3C) plasma from a mother-neonate pair delivery at
preterm (VLDW). As inferred from Figure 2A, there was no
noticeable difference between spectra from arterial and venous
umbilical cord plasma. In contrast, the spectrum of the maternal
plasma is dominated by a broad envelope of protein and lipid
resonances, virtually absent in the umbilical plasma samples.
Signals are assigned to LDL, VLDL, lipoproteins, N-acetyl groups
of glycoproteins and unsaturated lipids. Additionally, the aromatic
region of the maternal plasma spectrum (d 6–9 ppm) also shows
marked differences from both the arterial and venous umbilical
cord plasmas (Figure 4A), with an increase of signals at 6.80, 6.93,
7.23, 7.68 ppm (Figure 4B). These signals are probably due to
the presence of macromolecules, such as lipids and/or proteins.
These results confirmed those found in previous studies by
classical techniques, where an elevation of plasma lipids was
Figure 4. 500 MHz 1H NMR CPMG spectra for the aromatic region of blood plasma samples from a VLBW delivery. (A) Arterial cord
blood, (B) Maternal blood. The maternal plasma shows signals at 6.80, 6.93, 7.23 and 7.68 ppm that are absent from the preterm plasma.
doi:10.1371/journal.pone.0029947.g004
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pregnancy, with an increase in triglyceride, total cholesterol,
VLDL, HDL and LDL levels [26–28], along with lipid levels in
foetal umbilical cord and neonatal plasma below those reported in
adults [29,30], meeting maternal [31] and developing foetal [32]
energy requirements in late gestation.
Amino acid concentrations have been known to be significantly
higher in foetal than in maternal blood, considered to reflect the
presence of active transport systems within the placenta [1]. The
placenta also has the capacity for utilization, production, and
interconversion of amino acids, all of which can profoundly affect
the quantity of an amino acid delivered into the foetal circulation.
Among the 16 analysed maternal plasmas, one sample displayed
an unexpected biochemical profile, showing the most negative
scores (outlier at the bottom left of the score plot Figure 2A).
When this spectrum was scrutinised, triplet and quadruplet
resonances at 1.18 and 3.65 ppm, for the methyl and methylene
groups of ethanol were unexpectedly detected (Figure 5)
accompanied by another triplet at 1.05 ppm which was unique
to this
1H NMR spectrum (possibly the methyl group of
propionate). Contamination during handling was ruled out as a
potential source of ethanol. This atypical biochemical profile also
showed a disturbed lipid composition and a depletion of amino
acids in the maternal plasma. Intriguingly, however, neither an
enhanced level of ethanol nor any other evident change was seen
in the arterial and venous umbilical cord plasma from this
mother–infant pair. The same preservation in cord plasma amino
acid concentrations was observed in the plasma from rat pups
born from dams that had a severe diet-induced depletion of total
plasmatic amino acids [33]. This finding is consistent with the
previous study of venous umbilical cord plasma by
1H NMR,
wherein ethanol was identified in 5 venous umbilical cord plasma
samples, suggesting ethanol to be endogenous. In fact, a majority
of the
1H NMR spectra from both maternal and cord blood
showed traces of ethanol (Figure 5). Endogenous ethanol is
known to be produced in small quantity in mammalian tissue [34]
via the reduction of acetaldehyde, itself derived from the
decarboxylation of pyruvate [35]. This finding is consistent with
the hypothesis that endogenous ethanol is produced as an
intermediate step for the elimination of excess energy-releasing
substrates from mitochondria [36,37] as by the human body
during intense physical effort.
Effect of preterm delivery on maternal plasma
metabolomics
Analysis by PCA of the
1H CPMG NMR spectra of plasma
collected from mothers delivering either FT or VLBW infants
reveals differences between the two groups (Figure 6A). The
metabolites responsible for these differences were assessed with the
loading plot from PCA (data not shown) and by univariate statistical
tests of each metabolite (Table 2). Compared with mothers
delivering atFT,mothers delivering VLBW infants had significantly
higher levels of lipids, pyruvate, glutamine, valine and threonine,
and significantly lower levels of acetate and isoleucine. Although not
statistically significant (p=0.08), there was an increase in the N-
acetyl signals from the glycoproteins in the blood of preterm
mothers (Table 2). These signals arising from acute phase
glycoproteins [38] are known to reflect inflammatory status [39,40].
Effect of gestational age on venous umbilical cord
plasma of FT and VLBW infants
No significant overall differences between venous umbilical cord
plasma collected from mothers delivering at term or prematurely
were revealed by PLS-DA of the
1H CPMG or NOESYPR1D
NMRspectra. However, univariatestatistical testing indicated some
biomarkers to differ significantly. As shown in Table 2, significant
decreases in levels of lipids, HDL, VLDL, LDL, pyruvate, glucose,
acetone, albumin-lysyl, and significant increases in levels of formate
Figure 5. 500 MHz
1H NMR CPMG spectra of maternal, cord venous and cord arterial plasma. Note the presence of traces ethanol in most
spectra and high ethanol and possibly propionate (1.05 ppm) in one unusual maternal profile (the top one). This figure also shows the differences in
lipids between maternal and cord plasma (higher levels of lipid signals at 0.90, 1.23, 1.72 and 2.00 ppm) and in lysine levels (signals at 1.71 and
1.90 ppm higher in maternal plasma).
doi:10.1371/journal.pone.0029947.g005
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plasma collected from VLBW preterm delivery. A lower level of
lysyl groups of albumin is indicative of a degree of oxidative stress
[41]. It has recently been suggested that normal pregnancy is
associated with a level of relative hypoxia with the addition of
reperfusion and oxidative stress [42], and the amounts of albumin-
lysyl may reflect increased oxidative stress in the case of the VLBW
materno-foetal unit, despite the prevalence of caesarean delivery.
Note that more than half the VLBW group suffered from
hypertension (Table 1). Although the levels of glucose were similar
in the plasma of mothers delivering at FT and preterm (with a trend
on lower levels for the latter), glucose levels were 1.5-fold lower in
the venous cord plasma of VLBW compared with FT neonates, and
2-fold lower in arterial cord plasma (see next section). Interactions
between maternal glucose and foetal growth are not completely
understood but there may be a causal link between low maternal
blood glucose and low birth weight [43].
Biochemical alterations in arterial umbilical cord plasma
of FT and VLBW infants
Analysis of
1H NOESYPR1D spectra from all arterial plasma
samples by PLS-DA revealed metabolic variations related to the
term of delivery (Figure 6B). Most metabolite levels in arterial
umbilical cord plasma from preterm infants were significantly
different from those in venous umbilical cord plasma (Table 2).
Significant decreases in the level of HDL, LDL, VLDL, pyruvate,
glucose, acetone, albumin-lysyl, alanine, tyrosine, valine, isoleu-
cine, leucine, threonine and 3-methyl-histidine were observed in
arterial cord plasma from VLBW infants, accompanied by an
increase in glutamine levels. Hence, it is apparent that the
1H
NMR spectra obtained made it possible to identify several
biomarkers associated with VLBW infants. As for the venous cord
plasma, the levels of the albumin-lysyl residues were noticeably
lower in arterial umbilical cord plasma samples from preterm
delivery, indicating again the presence of foetal oxidative stress.
This result is in agreement with the known depletion in GSH
documented in VLBW infants compared with full-term neonates
[44]. Glutamine levels were elevated in both the venous and
arterial cord blood plasma of VLBW neonates: the reason for this
is not clear. It is noteworthy, however, that glutamine is the most
abundant amino acid in blood and is involved in multiple
pathways including the biosynthesis of purines and pyrimidines
[45], and the supply of energy to neonatal gut [46] and to other
rapidly dividing cells. Moreover, glucocorticoids, which are
secreted in excess during stressful situations, have been shown to
enhance both the de novo synthesis and the utilization of glutamine
[47]. As preterm birth is associated with significant stress, we
speculate that the increase of glutamine reflects a dramatic surge in
glutamine biosynthesis and placental transfer in order to cover the
need of the stressed preterm infant. Increased rates of glutamine
production have been reported in VLBW infants [46,48], and
Figure 6. Multivariate analyses resulting from the standard 1D 500 MHz
1H NMR spectra from FT and VLBW preterm deliveries. (A):
PCA scores plot resulting from the analysis of maternal plasma. (B): PLS-DA scores plot resulting from the analysis of arterial umbilical cord plasma
and validation by permutation test (C). (C): R
2(X)=0.366, R
2(Y)=0.695 and Q
2(Cum)=0.676. The model has been validated by a permutation test
(n=20). R
2 intercept is at 0.495 and Q
2 intercept is at 20.212.
doi:10.1371/journal.pone.0029947.g006
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malformed foetuses [49]. Most essential and non-essential amino
acids were depleted in VLBW plasma compared with FT plasma
(Table 2). Placental amino acid transport can be reduced due to
either impaired foetal and placental growth or to decreased
transporter concentrations [1]. Decreased transporter capacity has
been found in human IUGR placental vesicles [50], bearing out in
vivo studies that indicate decreased transport in IUGR pregnancies
[10,11].
Maternal-to-venous gradients for FT and VLBW infants
Univariate statistical tests were performed on the values of
nutrient gradients for maternal-to-venous (M-V) umbilical cord
plasma of FT and VLBW infants. Negative values of these gradients
reflect a net transfer from maternal circulation to the foetus,
whereas positive values mean that the transfer from the mother to
the foetus may be deficient. M-V gradients differed significantly
between VLBW and FT infants (Table 2). Significant increases of
HDL, lipids, glucose and histidinewereobserved inpreterminfants,
Table 2. Maternal and cord blood plasma metabolite differences between full-term and VLBW subjects.
Maternal plasma Venous cord plasma Arterial cord plasma Gradient M-V
Metabolite chemical shift ppm FT VLBW p
{ FT VLBW p
{ FT VLBW p
{ FT VLBW p
{
Lipoproteins
HDL 0.671 0.60 0.61 0.70 0.74 0.68 0.02* 0.74 0.66 0.05* 20.11 20.06 0.11
LDL 0.83 2.27 2.72 0.30 1.16 0.87 0.02* 0.98 0.67 0.04* 1.11 1.82 0.16
lipids 1.25 4.65 7.72 0.01# 1.88 1.43 0.30 1.56 1.11 0.20 2.77 5.81 0.03*
lipids 1.3 5.37 8.06 0.03* 1.96 1.46 0.35 1.56 1.23 0.42 3.41 5.97 0.06
VLDL 1.571 1.80 1.83 0.85 1.67 1.59 0.02* 1.67 1.59 0.01# 0.12 0.22 0.56
unsaturated
lipids 5.31
0.41 0.64 0.03* 0.20 0.10 0.05* 0.16 0.17 0.91 0.21 0.49 0.02*
Glycolysis pathway
Lactate 1.321 6.96 6.96 0.50 6.28 7.14 0.42 6.52 7.47 0.35 0.67 20.33 0.20
Acetate 1.91 0.62 0.31 0.01# 0.43 0.51 0.16 0.70 0.58 0.56 0.19 20.20 0.03*
Pyruvate 2.37 0.31 0.61 0.00# 0.80 0.64 0.05* 0.80 0.55 0.04* 20.48 20.03 0.00#
Glucose 3.7 4.46 3.67 0.21 5.81 3.52 0.01# 5.31 2.57 0.01# 21.79 0.26 0.01#
Glucose and/or glycerol 3.87 0.89 0.90 0.77 1.01 0.98 0.56 1.01 0.90 0.02* 20.13 20.07 0.16
Formate 8.45 0.02 0.02 0.44 0.03 0.06 0.02* 0.07 0.08 0.64 20.01 20.04 0.08
Ketone bodies
3-Hydroxybutyrate 1.20 2.87 1.06 0.12 0.91 0.57 0.11 0.60 0.42 0.06 1.96 0.41 0.35
Acetone 2.23 1.47 1.28 0.29 1.62 1.02 0.00# 1.39 0.86 0.01# 20.15 0.20 0.30
Proteins
N-Acetyl-glycoprotein 2.04 2.64 3.14 0.08 1.76 1.49 0.06 1.61 1.22 0.04* 0.88 1.57 0.08
Albumin-lysyl 2.91 0.48 0.44 0.21 0.88 0.81 0.01# 0.90 0.84 0.13 20.29 20.25 0.56
Albumin-lysyl 3.011 0.78 0.73 0.29 1.31 1.21 0.06 1.32 1.20 0.03* 20.57 20.48 0.49
creatinine 4.051 0.53 0.59 0.03 0.77 0.74 0.42 0.79 0.68 0.03 20.24 20.16 0.08
Amino acids
Non-essential
Alanine 1.47 0.67 0.72 0.85 1.26 1.11 0.20 1.20 0.81 0.04* 20.59 20.38 0.11
Glutamine/glutamate 2.131 1.10 1.33 0.01# 1.46 1.62 0.05* 1.42 1.42 0.56 20.28 20.25 0.73
Glutamine 2.45 0.36 0.51 0.05* 0.43 0.77 0.00# 0.43 0.67 0.03* 20.07 20.26 0.04*
Tyrosine 6.891 0.21 0.20 0.15 0.36 0.35 0.35 0.37 0.33 0.01# 20.15 20.14 0.91
Tyrosine 7.181 0.24 0.24 0.85 0.41 0.39 0.35 0.42 0.37 0.01# 20.17 20.15 0.49
Essential
Valine 0.98 0.59 0.86 0.00# 1.11 1.27 0.25 1.03 0.95 0.35 20.53 20.45 0.91
Valine 1.031 1.39 1.38 0.21 1.73 1.73 0.91 1.73 1.63 0.04* 20.34 20.11 1.00
Isoleucine 1.011 1.54 1.50 0.03* 1.69 1.61 0.16 1.69 1.52 0.03* 20.14 20.11 0.82
Leucine 1.711 0.18 0.20 0.44 0.37 0.39 0.49 0.39 0.31 0.11 20.19 20.20 0.64
Threonine 4.241 0.39 0.44 0.04* 0.56 0.51 0.08 0.58 0.46 0.01* 20.17 20.08 0.06
Methylhistidine 7.741 0.14 0.15 0.50 0.27 0.25 0.06 0.28 0.23 0.00# 20.12 20.09 0.04*
Values are given as area normalized peak signals mean (n=8 for each group).
1designates spectral signals integrated from NOESY spectra, all other signals being integrated from CPMG spectra.
{Significant differences at p,0.01 and p,0.05 are designated by # and *, respectively.
doi:10.1371/journal.pone.0029947.t002
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foetus. A low transfer of lipids may reflect the limited adipose
storage of the foetus until the third semester of the pregnancy [51],
rather than an increase of b-oxidation in foetal tissues due to a
greater use of free fatty acids, as the foetus is believed to cover its
energy needs solely with the oxidation of glucose.
In agreement with previous studies showing the existence of
active glutamine transport from the maternal compartment to
foetal blood [1,2], a decrease in the glutamine gradient was
observed in both groups, indicative of the utilization of this
metabolite by the placenta. Placenta is known to transaminate
other amino acids such as leucine, isoleucine and valine to their
respective a-ketoacids, which are released into the umbilical and
uterine circulation and contribute to placental ammonia produc-
tion, consistent with the high level of b-hydroxybutyrate and
acetate found in maternal plasma.
Conclusions
Based on a detailed analysis of
1H NMR spectra from maternal
plasma and both venous and arterial umbilical cord blood plasma,
a number of metabolites can be shown to vary depending on the
term of delivery. In particular, profiles of both maternal and
arterial umbilical cord plasma highlighted potential differences in
materno-foetal nutrient transfer and, probably, short-term changes
associated with birth-related oxidative stress. Thus, it can be
proposed that cord blood
1H NMR spectroscopy has considerable
potential as a rapid and non-invasive tool to investigate the
biochemical status in preterm delivery, including in VLBW
infants. The identification of a number of VLBW-related
biomarkers may also aid in evaluating the pre-parturition
nutritional status of the neonate and in providing guidance to
the design new strategies of supplementation with specific nutrients
in VLBW newborns.
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